Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Abbott Assumes Funding of SpectRx, Glucose Monitoring Product
Apr 2001
NORCROSS, Ga., April 13 -- SpectRx Inc. said that, as planned, its partner Abbott Laboratories has assumed financial responsibility for its continuous glucose monitoring program, as of April 1, 2001. Previously, SpectRx had been funding part of the research and development program.
    Abbott has exclusive worldwide marketing rights to SpectRx's interstitial fluid (ISF) glucose monitoring technology. Under the agreement, SpectRx will receive a royalty on sales of disposables and has the option to manufacture continuous monitoring devices for Abbott. The technology is being developed with Abbott. The technology measures glucose levels in ISF rather than blood. A stream of ISF is collected through an array of microscopic holes or micropores created with a laser in the outer layer of skin and measured in a patch containing a glucose sensor.

News & FeaturesSensors & Detectors

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.